BT
BTAI.US BioXcel Therapeutics Inc
- Market cap
- USD 2.31M
- P/E
- -
- P/B
- 27.50x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is BTAI.US undervalued?
Graham numberThe Graham number of BioXcel Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
BioXcel Therapeutics Inc fundamental analysis
No fundamental analysis for BioXcel Therapeutics Inc yet.
BioXcel Therapeutics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About BioXcel Therapeutics Inc
BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States. The company IGALMI, a sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. It also develops its neuroscience candidate, BXCL501, which is an investigational…
Full company profileBioXcel Therapeutics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
BioXcel Therapeutics Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 24.30 | 0.00 | 375K | 1.38M | 2.27M | 642K | 776K |
| Gross Profit | 0.00 | -1.00K | -17.0K | -156K | 24.30 | -297K | 355K | 120K | 123K | 478K | 50.0K |
| Operating Income | -2.12M | -4.54M | -20.0M | -33.6M | -82.3M | -107M | -160M | -172M | -67.2M | -50.3M | -40.6M |
| EBITDA | -2.12M | -4.54M | -19.3M | -32.8M | -82.1M | -107M | -157M | -165M | -44.2M | -52.6M | -37.7M |
| Net Income | -2.12M | -4.54M | -19.3M | -32.3M | -82.0M | -107M | -166M | -179M | -59.6M | -69.9M | -54.8M |
| EPS | -2.06 | -4.41 | -21 | -32 | -61 | -65 | -95 | -98 | -24 | -5.73 | -4.49 |
| Balance Sheet | |||||||||||
| Total Assets | 7.00K | 1.36M | 43.5M | 36.4M | 220M | 239M | 206M | 73.7M | 38.3M | 44.9M | 28.8M |
| Total Liabilities | 331K | 2.34M | 4.66M | 9.50M | 13.2M | 17.8M | 129M | 130M | 131M | 140M | 144M |
| Shareholders' Equity | -324K | -982K | 38.9M | 26.9M | 207M | 222M | 76.8M | -56.5M | -93.1M | -95.5M | -115M |
| Cash & Short-term Investments | 0.00 | 887K | 42.6M | 32.4M | 213M | 233M | 194M | 65.2M | 29.9M | 28.4M | 12.8M |
| Total Debt | - | 371K | - | 1.03M | 1.64M | 1.40M | 94.2M | 101M | 103M | 110M | 104M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -1.29M | -2.20M | -13.5M | -27.3M | -66.4M | -82.2M | -135M | -155M | -72.0M | -57.6M | -35.8M |
| Capital Expenditure | 4.00K | 340K | 340K | 870K | 316K | 445K | 139K | 20.0K | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -1.30M | -2.20M | -13.8M | -28.2M | -66.7M | -82.6M | -135M | -155M | -72.0M | -57.6M | -35.8M |
| Ratios | |||||||||||
| ROE | - | - | -49.6% | -120.2% | -39.7% | -48.1% | -215.9% | - | - | - | - |
| ROA | -30,285.7% | -335.0% | -44.2% | -88.9% | -37.3% | -44.5% | -80.5% | -242.9% | -155.5% | -155.6% | -190.3% |
| Net Profit Margin | - | - | - | - | -337,481,481.5% | - | -44,201.9% | -12,974.9% | -2,630.1% | -10,887.4% | -7,062.9% |
| Debt to Equity | - | - | - | 0.04x | 0.01x | 0.01x | 1.23x | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
BioXcel Therapeutics Inc dividends
BioXcel Therapeutics Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:16 on Feb 10, 2025.
Who owns BioXcel Therapeutics Inc
- Insiders 0.00%
- Institutions 10.28%
- Public & others 89.72%
- Shares outstanding 31.3M
- Free float 26.9M
Top funds holding BTAI.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 680K | 2.17% | 0.00% | Jul 2026 |
| Vanguard Institutional Extnd Mkt Idx Tr | 240K | 0.77% | 0.00% | Jul 2026 |
| Fidelity Extended Market Index | 126K | 0.40% | -0.19% | Jul 2026 |
| Fidelity Select Biotechnology | 90.3K | 0.29% | 0.00% | Jul 2026 |
| iShares Micro-Cap ETF | 88.6K | 0.28% | -1.95% | Aug 2026 |
| Blackrock Extended Mkt Fund CF | 69.3K | 0.22% | 0.00% | May 2026 |
| Extended Equity Market Fund B | 69.3K | 0.22% | 0.00% | Dec 2025 |
| Extended Equity Market Fund E | 69.3K | 0.22% | 0.00% | Dec 2025 |
| BlackRock Extended Equity Market Fund K | 58.9K | 0.19% | -0.18% | Jun 2026 |
| Fidelity Total Market Index | 34.2K | 0.11% | 0.00% | Jul 2026 |
| NT Ext Equity Mkt Index Fund - Lending | 31.3K | 0.10% | +133.06% | Jun 2026 |
| Northern Trust Extended Eq Market Idx | 31.3K | 0.10% | +133.06% | Jun 2026 |
| Fidelity Series Total Market Index | 29.5K | 0.09% | 0.00% | Jul 2026 |
| Spartan Extended Market Index Pool F | 25.8K | 0.08% | +0.92% | Jul 2026 |
| NT Ext Equity Mkt Index Fund - NL | 24.3K | 0.08% | +9.58% | Jun 2026 |
| Oaktree Diversified Income Fund Inc D | 20.4K | 0.07% | +472.22% | Jun 2026 |
| NT Ext Equity Mkt Idx Fd - DC - NL - T2 | 17.6K | 0.06% | +1.46% | Jun 2026 |
| Spartan Total Market Index Pool A1 | 15.4K | 0.05% | 0.00% | Jul 2026 |
| Oaktree Strategic Credit I | 12.7K | 0.04% | +1.50% | Mar 2026 |
| Fidelity Nasdaq Composite Index | 10.9K | 0.03% | 0.00% | Jul 2026 |
Top institutions holding BTAI.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Millennium Management LLC | 2.11M | 6.76% | +9.19% | Jun 2026 |
| Armistice Capital, LLC | 1.91M | 6.10% | 0.00% | Mar 2026 |
| Oaktree Capital Management LLC | 241K | 0.77% | 0.00% | Mar 2026 |
| Geode Capital Management, LLC | 230K | 0.74% | +11.64% | Mar 2026 |
| Vanguard Capital Management, LLC | 207K | 0.66% | 0.00% | Mar 2026 |
| Citadel Advisors Llc | 149K | 0.48% | 0.00% | Jun 2026 |
| JONES FINANCIAL COMPANIES LLLP | 132K | 0.42% | -4.29% | Mar 2026 |
| Man Group PLC | 96.5K | 0.31% | +69.77% | Mar 2026 |
| State Street Corp | 92.1K | 0.29% | +45.71% | Mar 2026 |
| FMR Inc | 90.3K | 0.29% | 0.00% | Mar 2026 |
| Vanguard Fiduciary Trust Co | 84.9K | 0.27% | 0.00% | Mar 2026 |
| BlackRock Inc | 84.3K | 0.27% | -0.14% | Mar 2026 |
| Wiley Bros.-Aintree Capital, LLC | 80.9K | 0.26% | 0.00% | Mar 2026 |
| UBS Group AG | 52.8K | 0.17% | +37.68% | Mar 2026 |
| Oaktree Fund Advisors, LLC | 42.9K | 0.14% | 0.00% | Mar 2026 |
| HighTower Advisors, LLC | 41.0K | 0.13% | 0.00% | Mar 2026 |
| Quadrature Capital Limited | 38.0K | 0.12% | 0.00% | Jun 2026 |
| Northern Trust Corp | 36.3K | 0.12% | -5.36% | Mar 2026 |
| Beacon Pointe Advisors, LLC | 18.9K | 0.06% | 0.00% | Mar 2026 |
| Portfolio Strategies, Inc. | 16.8K | 0.05% | +38.21% | Jun 2026 |
BioXcel Therapeutics Inc company profile
- Company name
- BioXcel Therapeutics Inc
- Ticker
- BTAI.US
- Exchange
- USA Stocks
- Listed since
- Mar 8, 2018
- Sector
- -
- Industry
- Biotechnology
- Employees
- 29
- Fiscal year end
- December
- Address
- 555 Long Wharf Drive, New Haven, CT, United States, 06511
- Phone
- 475 238 6837
- Website
- bioxceltherapeutics.com
About BioXcel Therapeutics Inc
BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States. The company IGALMI, a sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. It also develops its neuroscience candidate, BXCL501, which is an investigational, proprietary, orally dissolving sublingual film formulation of dexmedetomidine in Phase 3 trial for the treatment of agitation associated with bipolar disorders, schizophrenia, and Alzheimer's disease, as well as opioid use disorder, alcohol use disorder with comorbid post-traumatic stress disorder, and acute stress disorder; and its immune-oncology candidate, BXCL701, which is an investigational oral innate immune activator that has completed Phase 1b/2a trial for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors. In addition, the company engages in the development of BXCL502 for the treatment of stress-related neuropsychiatric symptoms in dementia and other stress-related disorders; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, which has the potential to address apathy and aggression in dementia. The company has collaborations with Columbia University, Yale University Medical School, and University of North Carolina for the development of BXCL501. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut. On August 27, 2026, BioXcel Therapeutics, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
BioXcel Therapeutics Inc management
6- Dr. Vimal D. Mehta Ph.D.Founder, CEO, President, & Director · born 1962
- Mr. Richard I. Steinhart MBASenior VP & CFO · born 1957
- Mr. Javier Rodriguez J.D.Senior VP, Chief Legal Officer & Corporate Secretary · born 1973
- Dr. Frank D. Yocca Ph.D.Executive VP & Chief Scientific Officer · born 1957
- Mr. Mark H. PavaoActing Chief Commercial Officer · born 1964
- Mr. Matt MandelVice President of Clinical Development